NCT-58 / Korea University, Seoul National University - LARVOL DELTA

HSP90 is involved in curcumin-mediated inhibition of tau aggregation. (PubMed, Biochem Biophys Res Commun) - "The reduced luciferase activity in the Tau-NLuc system by CCM was recovered by knockdown of the HSP90 gene using a siRNA specific for HSP90 or treatment of an inhibitor of HSP90 NCT-58, supporting the involvement of HSP90. Intriguingly, hexahydrocurcumin (HHC), a derivative of CCM, did not reduce luciferase activity, nor did it induce the formation of the HSP90 dimer, suggesting that HSP90 dimer formation may contribute to the CCM-mediated inhibition of tau aggregation. Taken together, the results demonstrate that CCM inhibits tau aggregation with the involvement of HSP90, providing novel insights into the development of therapeutic strategies for AD."

Journal • Alzheimer's Disease • CNS Disorders • CDC37 • HSP90AA1

A novel C-terminal HSP90 inhibitor NCT-58 targets cancer stem-like properties and suppresses migratory ability in triple-negative breast cancer cells (AACR 2022) - "These findings suggest that NCT-58 may represent an effective therapeutic approach for the simultaneous targeting of HSP90 and its client oncoproteins for the treatment of molecularly heterogeneous TNBC."

Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ALDH1A1 • CD24 • CD44 • STAT3 • VIM